Lilly Seeks Emergency Use Of Its Antibody Drug For COVID-19
A drug company says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on early results from a study that suggested the drug reduced symptoms, the amount of virus, hospitalizations and ER visits for patients with mild or moderate COVID-19.
Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.
Its drug is similar to one that President Donald Trump received on Friday from Regeneron Pharmaceuticals Inc. These medicines supply concentrated versions of specific antibodies to help the immune system clear the coronavirus that causes COVID-19. They’re given as a one-time treatment through an IV.
Lilly has already started making one of the two antibodies in its drug, betting that ongoing studies would prove it worthwhile.
It’s not clear if the evidence will be viewed as strong enough for the Food and Drug Administration to grant emergency use authorization, as it has done for the antiviral drug remdesivir.
The results are an interim look at a mid-stage study in which 112 people received the antibodies and 156 got a placebo.
The amount of virus was significantly lower 11 days later in those given the drug -- the main goal of the study. Virus also was lower at earlier time points as well. Symptom scores were better at three days.
About 5.8% of patients given placebo required hospitalization or an emergency room visit versus 0.9% of those given the antibodies.
The company said there were no serious drug-related side effects.
Marilynn Marchione can be followed on Twitter: @MMarchioneAP
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.


QuinStreet and AutoWeb Announce Strategic Relationship to Support Car Buyers
Startup Company Value Insurance Goes Live with BindExpress from SpeedBuilder Systems
Advisor News
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
- The 6X Formula for leveraging content marketing with AI
- When a home becomes difficult to insure, the plan changes
More Advisor NewsAnnuity News
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
- John Hancock launches new fixed indexed annuity suite
More Annuity NewsHealth/Employee Benefits News
- High costs inhibit Nebraskans from seeking healthcare, poll shows
- Franklin County Hiring Juvenile Probation Officer
- Soaring drug costs squeeze largest Mass. insurer, fueling $43.5M loss
- Health insurers leave Ohio marketplace
- Rising hospital, drug costs boost health insurance premiums at fastest pace since start of Obamacare
More Health/Employee Benefits NewsLife Insurance News
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Non-Life Insurance Segment
- AM Best Affirms Credit Ratings of Fubon Insurance Vietnam Co., Ltd.
- Three lawsuits put life insurers’ cost-of-insurance practices under scrutiny
More Life Insurance News